Artia Global Partners LP Takes Position in Palisade Bio, Inc. $PALI

Artia Global Partners LP bought a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 1,992,367 shares of the company’s stock, valued at approximately $4,682,000. Palisade Bio makes up 0.6% of Artia Global Partners LP’s portfolio, making the stock its 23rd largest position.

Several other institutional investors have also made changes to their positions in PALI. Total Clarity Wealth Management Inc. acquired a new stake in shares of Palisade Bio during the 4th quarter valued at about $70,000. Jefferies Financial Group Inc. acquired a new stake in shares of Palisade Bio during the 4th quarter valued at about $110,000. Geode Capital Management LLC boosted its position in shares of Palisade Bio by 5,780.7% during the 4th quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock valued at $3,681,000 after acquiring an additional 1,538,832 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Palisade Bio during the 4th quarter valued at about $1,310,000. Finally, TD Asset Management Inc acquired a new stake in shares of Palisade Bio during the 4th quarter valued at about $480,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Weiss Ratings lowered shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Wolfe Research initiated coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price target on the stock. HC Wainwright initiated coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price target on the stock. Stifel Nicolaus initiated coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.20.

Palisade Bio Stock Down 1.1%

NASDAQ:PALI opened at $1.76 on Thursday. The firm has a market cap of $305.50 million, a PE ratio of -1.74 and a beta of 1.52. Palisade Bio, Inc. has a 12 month low of $0.53 and a 12 month high of $2.86. The company’s 50-day moving average price is $1.97 and its two-hundred day moving average price is $1.90.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, research analysts expect that Palisade Bio, Inc. will post -0.21 EPS for the current fiscal year.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.